Showing results (331-340 of 364) with videos related to

Sort By:
Pageof 37
Neuro-Oncology|February 17, 2010
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I studyNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.
Biochimica Et Biophysica Acta|January 18, 2015
The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependentMing-Min Chung, Yen-Lin Chen, Dee Pei, et al.
Molecular and Cellular Biology|March 23, 2002
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol effluxTaro E Akiyama, Shuichi Sakai, Gilles Lambert, et al.
Ulusal Travma Ve Acil Cerrahi Dergisi = Turkish Journal of Trauma & Emergency Surgery : TJTES|November 12, 2013
Management of penetrating injuries of the upper extremitiesOscar J F Van Waes, Pradeep H Navsaria, Renske C M Verschuren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumChristopher J Sweeney, Bruce J Roth, Fairooz F Kabbinavar, et al.
Nucleic Acids Research|September 14, 2021
Theoretical basis for stabilizing messenger RNA through secondary structure designHannah K Wayment-Steele, Do Soon Kim, Christian A Choe, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2020
Theoretical basis for stabilizing messenger RNA through secondary structure designHannah K Wayment-Steele, Do Soon Kim, Christian A Choe, et al.
Investigational New Drugs|December 2, 2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancerStefan Madajewicz, David M Waterhouse, Paul S Ritch, et al.
Journal of Clinical Microbiology|February 14, 2014
Molecular epidemiology of merkel cell polyomavirus: evidence for geographically related variant genotypesClaire Martel-Jantin, Claudia Filippone, Patricia Tortevoye, et al.
Pageof 37